-
BridgeBio Pharma Inc NASDAQ:BBIO BridgeBio Pharma Inc. is a team of experienced drug discoverers, developers and innovators working to create life-altering medicines that target well-characterized genetic diseases at their source. BridgeBio was founded in 2015 to identify and advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. BridgeBio's pipeline of over 20 development programs includes product candidates ranging from early discovery to late-stage development.
Location: 421 Kipling St, California, 94301-1530, US | Website: bridgebio.com | Industry: Pharmaceutical Preparation Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
6.704B
Cash
266.3M
Avg Qtr Burn
-112.6M
Short % of Float
13.26%
Insider Ownership
5.40%
Institutional Own.
94.16%
Qtr Updated
09/30/24
Drug Pipeline
Powered by
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Attruby™ (Acoramidis) (AG10) Details Transthyretin Amyloid Cardiomyopathy | Approved Quarterly sales | |
NULIBRY (Fosdenopterin) (BBP-870/ORGN001) Details Molybdenum cofactor deficiency type A | Approved Quarterly sales | |
Infigratinib Details Achondroplasia | Phase 3 Data readout | |
BBP-418 Details Limb-Girdle Muscular Dystrophy | Phase 3 Data readout | |
Phase 3 Data readout | ||
Infigratinib Details Hypochondroplasia | Phase 2 Data readout | |
BBP-398 + OPDIVO Details Solid tumor/s, Lung cancer, Non-small cell lung carcinoma | Phase 1/2 Data readout | |
BBP- 812 Details Canavan disease | Phase 1/2 Update | |
BBO-8520 (KRASG12C inhibitor) Details Non-small cell lung carcinoma, Lung cancer, Solid tumor/s | Phase 1 Data readout | |
BBO-10203 Details Hyperglycemia | IND Submission | |
TRUSELTIQ (infigratinib) Details Cholangiocarcinoma | Failed Discontinued | |
BBP-631 Details Congenital adrenal hyperplasia | Failed Discontinued |